Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study by Richardson, Kathryn et al.
 1 
 
Adverse effects of Z-drugs for sleep disturbance in people living with dementia: 
a population-based cohort study 
 
Kathryn Richardson, Yoon K Loke, Chris Fox, Ian Maidment, Robert Howard, Nicholas Steel, Antony 
Arthur, Penelope J Boyd, Clare Aldus, Clive Ballard, George M Savva 
 
 
*Kathryn Richardson, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK 
Yoon K Loke, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK  
Chris Fox, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK 
Ian Maidment, School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK 
Robert Howard, Division of Psychiatry, University College London, UCL Division of Psychiatry, Maple 
House, 149 Tottenham Court Road, London, W1T 7NF, UK,  
Nicholas Steel, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ 
Antony Arthur, School of Health Sciences, University of East Anglia, Norwich, NR4 7TJ, UK, 
Penelope J Boyd, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK 
Clare Aldus, School of Health Sciences, University of East Anglia, Norwich, NR4 7TJ, UK,  
Clive Ballard, Medical School, University of Exeter, Exeter, EX1 2LU, UK,  
George M Savva, Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK, and 
School of Health Sciences, University of East Anglia, NR4 7TJ, UK 
 
*Correspondence to: K Richardson kathryn.richardson@uea.ac.uk, telephone: +44 (0)1603 591074   
 
 
 
Key words: dementia, Alzheimer disease, cohort studies, Sleep Initiation and Maintenance Disorders, 
benzodiazepines, Zolpidem, Hip Fractures, Accidental Falls 
 
 
Words = 4096 
  
 2 
 
List of abbreviations 
ATC Anatomical Therapeutic Chemical 
BMI Body Mass Index 
CPRD Clinical Practice Research Datalink 
DDD Defined Daily Doses 
GP General Practitioner 
HES Hospital Episode Statistics  
ICD-10 International classification of diseases 10th revision 
MEDALZ Medicine use and Alzheimer's disease 
NNH Number Needed to Harm 
ONS Office of National Statistics 
PlwD People living with Dementia 
PPI Patient and Public Involvement 
TCA Tricyclic Antidepressant 
 
  
 3 
 
ABSTRACT  
 
Background: Sleep disturbance is common in dementia and often treated with Z-drugs (zopiclone, 
zaleplon, and zolpidem). While some observational studies suggest that Z-drugs are associated with 
adverse events such as falls and fracture risks in older people, this has not been studied in dementia.   
Methods: We used data from 27,090 patients diagnosed with dementia between January 2000 and 
March 2016 from the Clinical Practice Research Datalink linked to Hospital Episodes Statistics data in 
England.  We compared adverse events for 3,532 patients newly prescribed Z-drugs by time-varying 
dosage to (1) 1,833 non-sedative-users with sleep disturbance, (2) 10,214 non-sedative-users with 
proximal GP consultation matched on age, sex, and antipsychotic use, and (3) 5,172 patients newly 
prescribed benzodiazepines. We defined higher dose Z-drugs and benzodiazepines as prescriptions 
equivalent to ≥7.5mg zopiclone or >5mg diazepam daily. Cox regression was used to estimate hazard 
ratios (HR) for incident fracture, hip fracture, fall, mortality, acute bacterial infection, ischaemic 
stroke/transient ischaemic attack, and venous thromboembolism over 2-year follow-up, adjusted for 
demographic and health related covariates. 
Results: The mean (SD) age of patients was 83 (7.7) years and 16,802 (62%) were women.  Of 3,532 
patients prescribed Z-drugs, 584 (17%) were initiated at higher doses. For patients prescribed higher dose 
Z-drugs relative to non-users with sleep disturbance, the HRs (95% confidence interval) for fractures, hip 
fractures, falls and ischaemic stroke were 1.67 (1.13-2.46), 1.96 (1.16-3.31), 1.33 (1.06-1.66) and 1.88 
(1.14-3.10).  We observed similar associations when compared to non-sedative-users with proximal GP 
consultation. Minimal or inconsistent excess risks were observed at ≤3.75mg zopiclone or equivalent 
daily, and for mortality, infection, and venous thromboembolism. We observed no differences in adverse 
events for Z-drugs compared to benzodiazepines, except lower mortality rates with Z-drugs (HR [95% 
confidence interval] of 0.73 [0.64-0.83]). 
Conclusions: Higher dose Z-drug use in dementia is associated with increased fracture and stroke risks, 
similar or greater to that for higher dose benzodiazepines. Higher dose Z-drugs should be avoided, if 
possible, in people living with dementia, and non-pharmacological alternatives preferentially considered. 
Prescriptions for higher dose Z-drugs in dementia should be regularly reviewed. 
TRIAL REGISTRATION: EUPAS18006 (ENCePP e-register of studies) 
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Background 
Around 60% of people living with dementia (PlwD) are affected by sleep disturbance [1,2], including 
insomnia, fragmented night time sleep, night-time wandering, or excessive day sleep [3].  Sleep 
disturbance affects the quality of life of PlwD and their informal carers, and often leads to care home 
admission [4].  
 
Benzodiazepines are frequently used for insomnia in PlwD and act by binding to gamma-aminobutyric 
acid, an inhibitory neurotransmitter [5].  Benzodiazepines are associated with a range of adverse side-
effects including cognitive impairment, daytime sedation, tolerance, dependence and falls [6–9].  Z-drugs 
(zaleplon, zopiclone, eszopiclone and zolpidem), a class of non-benzodiazepine gamma-aminobutyric acid 
agonists have shorter half-lives and were originally believed to be safer than benzodiazepines, but their 
adverse effects are increasingly recognised [10,11].  Observational studies report Z-drugs are associated 
with increased risks of falls, fractures, stroke, mortality and infection in older adults [12–16]. However, 
these studies are generally subject to residual confounding by sleep disturbance and comorbidity. Studies 
have also not typically examined how the timing and dosages of Z-drugs might modify risk. More 
importantly, the adverse effects of Z-drugs have rarely been studied in PlwD, where these side-effects 
can be particularly catastrophic [17]. A recent Cochrane review found insufficient evidence to guide drug 
treatment of sleep problems in dementia [18], despite wide scale prescribing [19]. In addition, the 
effectiveness of Z-drugs to improve sleep in older people is uncertain and considered limited [11], with 
cognitive behaviour therapy demonstrated to be more effective at managing insomnia than zopiclone in 
older adults [20]. 
 
We examined the association between first Z-drug prescription and subsequent risk of falls, fractures, 
mortality, infection, ischaemic stroke, and venous thromboembolism in PlwD. To reduce confounding, we 
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compared Z-drug users with (1) non-users with sleep disturbance, (2) non-users with a proximal GP 
consultation, and (3) new benzodiazepine use. 
Methods 
Study Design  
We performed a series of cohort studies, using data from the Clinical Practice Research Datalink (CPRD) 
linked to Hospital Episode Statistics (HES), Office for National Statistics (ONS) mortality data, and Index of 
Multiple Deprivation data in England. CPRD collates all diagnoses, referrals and prescribing records for 
over 11.3 million patients broadly representative of the UK population [21]. Diagnosis information is 
electronically entered as UK Read codes [22]. HES records all diagnoses made during a hospital admission 
(coded using the International classification of diseases 10th revision [ICD-10]) and demographic 
information [23], and ONS provides date and cause of death (ICD-10 coded) [24]. The Index of Multiple 
Deprivation combines a number of indicators of housing, employment, income, education, environment 
at the general practice level [25]. CPRD obtained ethical approval from a National Research Ethics Service 
Committee, allowing researchers to access anonymized data for observational studies upon approval 
from an Independent Scientific Advisory Committee. 
Study Population 
We defined dementia patients by record of a dementia diagnosis in CPRD (codes in Additional file 1) or 
HES (ICD-10 F00-F03, G30, G31.0 or G31.1) or prescription of a cognitive enhancer (i.e. memantine, 
donepezil, rivastigmine, or galantamine), occurring after January 2000 when aged ≥55 years. We 
excluded patients with <3 months of ‘up-to-standard’ (research quality) data or with severe mental illness 
or Down syndrome before dementia diagnosis (codes in Additional file 1) [21].  
 
Exposures 
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Our primary exposure was new prescription of Z-drugs. We considered three comparator groups to 
reduce confounding [26]. The primary comparator was record of sleep disturbance without sedative-
hypnotic prescription. Secondary comparators were (a) non-users at a proximal GP consultation and (b) 
new benzodiazepine users.  To facilitate these comparisons, three main cohorts were constructed, with 
their index date as the first date after dementia diagnosis of (a) prescription for a Z-drug (World Health 
Organization’s Anatomic Therapeutic Classification [ATC] system category N05CF), (b) prescription of any 
benzodiazepine (ATC N05BA or N05CD except midazolam injection), and (c) code for sleep disturbance 
(codes in Additional file 1) but without a concurrent sedative-hypnotic (ATC N05C or N05BA) prescription.  
 
Two additional cohorts were created by matching the Z-drug and BZD cohorts on age, sex and 
antipsychotic use, to non-users (not prescribed sedative-hypnotics) with proximal GP consultation. We 
matched three non-users to each Z-drug or benzodiazepine user, without replacement, and assigned an 
index date as the closest GP consultation within one month of the corresponding Z-drug or 
benzodiazepine index date. Patients could be members of different cohorts over time. 
 
Exclusion criteria for all cohorts were (1) <12 months data history, (2) sedative-hypnotic prescription in 
last 12 months, (3) prior diagnosis of sleep apnoea, sleep related respiratory failure, or alcohol abuse 
(codes in Additional file 1), (4) prescription of multiple sedative-hypnotics, and (5) newly prescribed 
antipsychotics or low dose tricyclic or related antidepressants (≤25 mg Amitriptyline or ≤50 mg Trazodone 
per day).  We additionally performed a separate validation study on the accuracy of our patient selection 
(details in Additional file 2). In summary, GP practices confirmed dementia diagnoses in 96% of cases, 
however uncertainty was raised regarding the accuracy of those identified with sleep disturbance. 
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To test dose-response relationships we determined the number of daily defined doses (DDDs) of Z-drugs 
and benzodiazepines at each prescription. The DDD is the assumed average maintenance dose per day 
for a drug based on its main indication in adults. We used DDD values from the World Health 
Organisation’s Collaborating Centre for Drug Statistics Methodology (www.whocc.no/atc_ddd_index), 
where the DDDs for zopiclone, zolpidem and zaleplon are 7.5mg, 10mg and 10mg per day. The British 
National Formulary recommends these daily doses for adults with insomnia, but to halve them for elderly 
patients. Missing dosing frequency data was assumed once daily, except diazepam where we applied the 
most common frequency for the product and quantity prescribed amongst the complete prescription 
data.  
 
 
Outcomes 
The selected outcomes were identified from previous studies or were priorities identified by our Patient 
and Public Involvement (PPI) group members or by an advisory group of healthcare professionals 
established to support this project. The main outcomes were, in order of importance: (1) Incident (a) 
fracture in any location, (b) hip fracture, and (c) forearm/wrist/hand fracture, (2) Incident fall, (3) 
mortality, (4) acute bacterial infection, (5) Ischaemic stroke/transient ischemic attack, and (6) Venous 
thromboembolism. These were identified via first mention of a relevant Read code in CPRD or ICD-10 
code in HES or ONS (codes in Additional file 3). We also examined further healthcare utilization 
outcomes: (7) number of (a) hospital admissions, and (b) GP consultations, and (8) new prescription of (a) 
antipsychotics (b) antidepressants, and (c) antibiotics.  
 
 
Covariates 
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We considered as potential confounders variables suspected to be linked to dementia, sleep disturbance, 
benzodiazepine or Z-drug use or the outcomes examined. They were measured on the index date and 
covered domains of demographics, health behaviours, dementia subtype, proxies for dementia severity, 
proxies for sleep disturbance severity, comorbidities, recent medical history (e.g. GP consultations, 
hospital admissions, falls, fractures, infections, immunisations, body mass index [BMI], systolic blood 
pressure), and concurrent prescriptions (details in additional file 4).   
 
Statistical analysis  
The primary analysis estimated the association between new prescription of sleep disturbance 
medication and incidence of each outcome, compared to other groups. We followed patients until the 
earliest of: death, leaving the GP practice, last data extraction, new sedative-hypnotic or antipsychotic 
prescription, 2-years post index date, or 31st March 2016. Z-drug and benzodiazepine new-users were 
also censored 90 days following their last Z-drug/benzodiazepine prescription. Matched patients were 
additionally censored at the censoring date of their corresponding case. Specific exclusion criteria applied 
at the index date to reduce the chance of repeated coding of the same event are described in Additional 
file 5 table S1.  
 
Cox proportional hazards regression was used for binary outcomes. We used robust standard errors to 
account for the correlation due to repeat measurements in some patients [27]. The proportional hazards 
assumption was checked using Schoenfeld residuals [28]. Negative binomial regression was used to 
model number of hospital admissions and GP consultations.  Estimates were adjusted for age and sex, 
and all covariates in additional file 4.  Age, BMI, systolic blood pressure, duration since dementia 
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diagnosis, index date, and number of prior GP consultations were modelled using restricted cubic splines 
(with five knots) to allow non-linear effects [29]. We included an interaction between sex and BMI, due to 
known sex differences in the relationship between BMI and fracture risk [30]. Absolute risk differences of 
adverse events and numbers needed to harm (NNH) were estimated using standard formulae for time to 
event analysis [31].  
 
We examined average daily Z-drug dose over follow-up, but in post-hoc secondary analysis, to reflect 
changes in dose, we examined time-varying daily DDDs.  In sensitivity analysis, we excluded those with 
record of >6 hours sleep per night from the sleep-disturbance comparator group (see validation study in 
Additional file 2 for more detail). This was to increase the chance that the sleep-disturbance group had 
more comparable insomnia to the Z-drug group. Finally, in the comparison of Z-drug to benzodiazepine 
new-users, we restricted to benzodiazepines likely prescribed for sleep disturbance (loprazolam, 
lormetazepam, nitrazepam, temazepam, or other benzodiazepine with dosing instructions to take only at 
night or with a concurrent record of sleep disturbance).  
 
Multiple imputation by chained equations was used to impute missing values of BMI, smoking, alcohol 
use, residence, ethnicity and blood pressure (see Additional file 4 for details) [32].  To account for 
multiple outcomes tested, we used the Benjamini-Hochberg procedure to control the false discovery rate 
at <5% for each analysis [33]. Stata version 15.1 was used throughout. 
 
Results 
 10 
 
There were 51,117 eligible dementia patients with ≥12 months data history in the linked CPRD-HES 
database (additional file 5 figure S1). Of these, 3,532 and 5,172 patients were newly prescribed Z-drugs or 
benzodiazepines respectively and met our inclusion criteria. Z-drug and benzodiazepine new users were 
matched to 10,214 and 15,174 non-users, respectively.  Finally, 1,833 dementia patients had recorded 
sleep disturbance, but without prescription of sedative-hypnotics. 
 
Patient characteristics 
The mean (SD) age of patients at index date was 83 (7.7) years, and 16,802 (62%) were women. Patients 
were registered with their GP for a median (IQR) of 19 (11-32) years and diagnosed with dementia for a 
median (IQR) of 12 (4-25) months. 
The patient cohorts were similar across measured characteristics (Table 1 with missing data described in 
additional file 5 table S2). Recent hospital admissions were more likely among Z-drug users. Concurrent 
antipsychotics and antidepressants, and previous benzodiazepine or Z-drug use was more likely among 
benzodiazepine and Z-drug users. Benzodiazepine users more frequently lived in care homes, had 
agitation/psychosis and anxiety and dementia for longer. Those with sleep disturbance (no sedative-
hypnotics) were more likely from a deprived neighbourhood, consume alcohol, have urinary 
incontinence, and insomnia history before dementia. Finally, the non-users with proximal GP consultation 
had more recent GP consultations and fewer recent falls and fractures. 
Of 3532 patients prescribed Z-drugs, 3358 (95%) were prescribed zopiclone, with 2801 (83%) prescribed 
3.75mg daily on the index date. For 598 (17%) the prescription instructions were “pro re nata” (PRN / as 
needed).  Of 5172 patients prescribed benzodiazepines, the most common were diazepam (n=2077, 
40%), lorazepam (n=1669, 32%) and temazepam (n=1168, 23%). Patients were followed for a median 
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(IQR) of 3.5 (3.0-10.3) months and mainly censored due to no further Z-drug or benzodiazepine 
prescriptions. See additional file 5 table S3 for initial and follow-up doses.  
 
Falls and fractures 
We estimated HRs (95% CI) of 1.32 (0.99-1.75) and 1.34 (1.08-1.67) for Z-drugs and fracture compared to 
sleep disturbance (without sedative-hypnotics) and non-use with proximal GP consultation, respectively 
(Table 2).  For hip fracture, the HRs (95% CI) were 1.38 (0.92-2.06) and 1.59 (1.15-2.19) for Z-drugs 
compared to sleep disturbance and non-use with proximal GP consultation, respectively. Z-drug use was 
associated with increased falls compared to non-use with proximal GP consultation (HR 1.43, 95% CI 1.26-
1.62), but not compared to sleep disturbance (HR 1.02, 95% CI 0.87-1.21). New benzodiazepine use was 
associated with increased fractures and falls compared to non-use with proximal GP consultation, but the 
HR (95% CI) for hip fractures was 1.17 (0.87-1.57) (additional file 5 table S4). There were no large 
differences in fall and fracture rates between new Z-drug and benzodiazepine users (Table 2).  
There was evidence of differing associations with the outcomes according to the prescribed daily dose of 
Z-drugs or benzodiazepines (Table 3 and additional file 5 table S5). Compared to sleep disturbance 
without sedative-hypnotics, the adjusted HR (95% CI) for fractures, hip fractures and falls for Z-drug 
prescriptions equivalent to ≥7.5mg zopiclone daily were 1.67 (1.13-2.46), 1.96 (1.16-3.31) and 1.33 (1.06-
1.66). The adjusted HR (95% CI) for Z-drug prescriptions equivalent to ≤3.75mg zopiclone daily and 
fractures, hip fractures and falls were 1.22 (0.90-1.66), 1.21 (0.78-1.90) and 0.95 (0.80-1.13). Similar 
associations were observed when compared to non-users with proximal GP consultation.   
Absolute risks. Use of zopiclone at ≥7.5 mg or equivalent is associated with absolute annual risks of 
fracture of 12.4% (compared to 7.6% in the sleep disturbance cohort). For hip fracture, the corresponding 
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figures are 6.6% annual risk associated with zopiclone at ≥7.5 mg or equivalent compared to 3.4%. This is 
equivalent to NNH of 21 and 32, and extra cases per 1000 treated of 48 and 32 for fractures and hip 
fractures, respectively. 
 
Mortality, infection and cardiovascular outcomes 
Although Z-drug use was associated with greater mortality compared to those with sleep disturbance (HR 
1.38, 95% CI 1.14-1.66), there was no strong evidence of excess risk compared to non-users with a 
proximal GP consultation (HR 1.08, 95% CI 0.94-1.23) (Table 2). Further, the associations with mortality 
seemed unrelated to dose (Table 3). Z-drug prescription was associated with less mortality than 
benzodiazepines (HR 0.73, 95% CI 0.64-0.83).  
We did not detect any strong associations between new Z-drug prescription and greater infection or 
venous thromboembolism rates, compared either to the non-users or benzodiazepine users. 
When examining new Z-drug prescription overall, we did not detect strong associations with incident 
stroke rates (HR 1.14 [95% CI 0.86-1.50], compared to non-users with proximal GP consultation). 
However, higher dose (≥7.5mg zopiclone or equivalent) Z-drugs were associated with more ischaemic 
strokes (HR 1.88 [95% CI 1.14-3.10] and 1.90 [1.30-2.79] compared to sleep disturbance and non-users 
with proximal GP consultation). The association for higher dose Z-drugs appeared greater than that for 
higher dose (>5mg diazepam or equivalent) benzodiazepine use, with a HR (95% CI) for higher dose 
benzodiazepine and stroke of 1.37 (0.91-2.08) compared to non-use with proximal GP consultation 
(additional file 5 table S5). 
 13 
 
Absolute risks. Use of zopiclone at ≥7.5 mg or equivalent is associated with absolute annual risks of stroke 
of 8.1% (compared to 4.4% in the sleep disturbance cohort).  This is equivalent to an NNH of 27 and 37 
extra cases per 1000 treated.   
 
Additional medication and healthcare utilisation 
The adjusted rate ratios (95% CI) for hospital visits for Z-drug users were 1.26 (1.13-1.40), compared to 
sleep disturbance and 1.17 (1.07-1.27), compared to non-use with proximal GP consultation. The rates 
between Z-drugs and benzodiazepines were similar. For GP consultations the corresponding rate ratios 
were 1.17 (1.12-1.23) and 1.07 (1.04-1.11), respectively. However, when analysed by time-varying 
prescribed dose, more frequent hospital admissions and GP consultations were generally only observed 
for higher dose Z-drugs (Table 5) and higher dose benzodiazepines (additional file 5 table S6).  
Z-drug users were more likely prescribed a new antipsychotic (HR 2.37, 95% CI 1.84-3.04) or 
antidepressant (HR 2.32, 95% CI 1.65-3.25) during follow-up compared to non-users with sleep 
disturbance (Table 4). There was a small increase in antibiotic prescribing subsequent to new Z-drug 
prescription compared to non-users with proximal GP consultation (HR 1.19, 95% CI 1.08-1.30). Rates of 
new prescribing were generally similar post Z-drug prescription to post benzodiazepine prescription and 
were greater with increasing Z-drug dose (Table 5). 
 
Additional analyses 
Similar associations to those for time-varying prescribed dose were observed when analysing the (non-
time-varying) average number of doses prescribed over the exposure period (additional file 5 table S7-
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S8). In the sensitivity analysis using a comparator of those with sleep disturbance and no associated 
mention of >6 hours sleep, associations for Z-drug use were generally slightly reduced (additional file 5 
tables S9-S10). Finally, associations for Z-drug use compared to the 1601 patients prescribed 
benzodiazepines for sleep disturbance were very similar to when comparing to any benzodiazepine 
(additional file 5, table S11).  
 
Discussion 
We found evidence of increased risks of falls, fractures and ischaemic stroke in people with dementia 
prescribed Z-drugs at higher doses.  The associations observed were similar or greater in magnitude to 
those for higher dose benzodiazepine prescription. One in six Z-drug prescriptions were commenced at 
higher doses of equivalent to 7.5mg zopiclone daily or greater.  We did not detect any consistent or 
clinically significant increased risks of mortality, infection or venous thromboembolism with Z-drug use. 
PlwD prescribed higher dose Z-drugs were also more likely to be admitted to hospital, visit their GP, and 
be further prescribed antipsychotics, antidepressants and antibiotics.  
 
We designed the study to minimize possible sources of bias [34].  Although we were unable to measure 
dementia severity, we adjusted for duration since the dementia diagnosis, prescription of dementia 
medications and antipsychotics, history of agitation/psychosis, and end of life care. However, there may 
be residual confounding by dementia severity for some comparisons.  Although underlying severity was 
unclear, Tthe mortality results suggest that, compared to Z-drug users, the sleep disturbance group not 
prescribed sedatives may have less severe dementia, however that the non-users with proximal GP 
consultation had comparable dementia severity.    Residual confounding by sleep disturbance severity is 
also a possibility.  Sleep disturbance was challenging to identify within the electronic primary care record 
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as highlighted in our validation study, where only 42% of our selected ‘sleep disturbance’ patients had 
sleep disturbance confirmed by their GP practice. This could be partly due to the sometimes 
contradictory ‘sleep pattern’ records or that the sleep disturbance recorded was transient or due other 
causes, such as urinary incontinence or alcohol abuse.  The comparable falls risk in the Z-drug and ‘sleep 
disturbance’ group could be due to urinary incontinence and alcohol use being more common in the 
‘sleep disturbance’ group.  The coding of ‘sleep disturbance’ was often vague and may represent 
conditions other than insomnia. It may be that some of the ‘sleep disturbance and no sedative’ group had 
milder cases of sleep disturbance than those prescribed Z-drugs.  Performing a sensitivity analysis on the 
sleep disturbance definition reduced our effects slightly.  Residual confounding by severity of insomnia or 
dementia could also affect the associations with higher Z-drug doses.  We also had no data on genetic 
information and environmental factors, which may influence falls risk in people living with dementia [35]. 
There was likely some small residual confounding due to new admission to a care home, however we 
were unable to accurately ascertain the admission date to control for this.  
 
Our study was strengthened by additional comparisons to non-users with a proximal GP visit and new 
benzodiazepine users. As benzodiazepines are also prescribed for anxiety and behavioural disturbances 
of dementia, there may be residual confounding by dementia and sleep disturbance severity in the 
comparison between Z-drug and benzodiazepine users. However, when instead restricting to 
benzodiazepines likely prescribed for sleep disturbance our findings were very similar. Dosing instructions 
were often missing for benzodiazepines, and although we made plausible assumptions based on the 
complete prescriptions, some misclassification of exposures is possible. Recording of prescriptions issued 
in primary care is accurate, however we lacked data on medications prescribed in secondary care or 
obtained elsewhere. Medication adherence is unknown, therefore the Z-drug effects may be 
underestimated if many patients prescribed Z-drugs had not taken them. Studies report high positive 
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predictive values for patients coded with our study outcomes in UK primary care data [36–41]. Potential 
under-reporting in CPRD was improved through linkage to HES and ONS. However, we likely under-
estimated forearm fracture incidence as many do not require hospital admission. Similarly, GP records of 
falls may under-represent all falls that occur in the older population, but more accurately represent 
‘injurious falls requiring medical attention’ [42].  Our study was strengthened by using a new-user design 
and careful selection and follow-up of patients taking Z-drugs alone and not concurrent with other 
sedative-hypnotics [43,44].  Our findings are generalizable to most people with diagnosed dementia and 
sleep disturbance.  Few patients were prescribed zaleplon or zolpidem and none eszopiclone; however as 
they exert the same pharmacological action as zopiclone, the adverse effects of these agents are likely 
similar.   
 
Comparison with other studies 
Fractures 
Few studies have examined Z-drug dose and fracture risk. Greater risks of hip fracture were reported 
among older US care-home residents taking higher dose Z-drugs, although limited by small numbers [45]. 
Additionally, few studies have examined fracture risk in PlwD taking Z-drugs. Consistent with our findings, 
a study of hospital records of PlwD in Japan reported increased fracture risks with Z-drug use, but they 
were unable to ascertain whether the prescription was given before or after the fracture [46].  Various 
studies report associations between Z-drugs and fracture risk, and specifically hip fracture risk, in older 
adults [12,13].  However, our study and others suggest this relative risk is lower in PlwD [47,48].  For 
example in US nursing home residents, greater odds ratios were estimated between non-benzodiazepine 
hypnotic drug use and hip fracture in residents with no or only mild cognitive impairment than with 
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moderate-severe cognitive impairment [47]. Z-drugs likely increase fracture risk through their effects on 
gait and balance [49,50].  A randomised trial reported more tandem walk failures upon night-time 
awakening among older adults randomized to 5mg zolpidem compared to placebo [51].  
 
Falls 
Z-drugs were originally claimed to cause fewer falls than benzodiazepines [52], however, we found similar 
or larger effects. This is consistent with findings from older men in the Osteoporotic Fractures in Men 
study [53].  More fall-related injuries were observed with Z-drug use in older people in Taiwan, with 
greater frequencies when prescribed >0.6 DDDs [54]. Increased fall rates have also been observed with 
dose increases in sedative-hypnotics in nursing home residents with dementia [55].  
 
Cardiovascular outcomes 
Similar to us, more strokes were observed in the Medicine use and Alzheimer's disease (MEDALZ) cohort 
prescribed Z-drugs and adults in Taiwan prescribed zolpidem [15,56].  Unfortunately, neither study 
estimated dose-specific risks. Mechanisms for Z-drugs causing increased stroke risk are uncertain, but 
could relate to decreased local cerebral blood flow [56]. However, as prolonged sleep disturbances likely 
increase stroke risk, residual confounding by sleep disturbance severity and duration could underlie 
reported associations [57].   
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Infections 
Analysis of RCT data, generally in younger adults, indicated possible 1.5-2 fold increased infection risks 
when taking zopiclone and zolpidem [58]. We found inconsistent evidence of increased bacterial infection 
risk with higher dose Z-drugs. Other studies in older adults, including a MEDALZ cohort study, report no 
association between Z-drug use and risk of pneumonia [59–61].   Together these suggest that if acute 
infection risk increases with higher dose Z-drug use in PlwD, then it is likely to be small, and our study was 
underpowered to detect it. 
 
Mortality 
Consistent with our findings, a MEDALZ cohort study found benzodiazepine use associated with increased 
mortality, but not Z-drugs [62].   Studies on Z-drug or benzodiazepine use and mortality in adults have 
been conflicting, and reported associations may simply stem from increased usage of benzodiazepines 
with approaching death [63].  
 
Healthcare Utilization  
We observed greater subsequent initiation of antipsychotics and antidepressants among Z-drug users, 
similarly observed by older people prescribed Z-drugs in a Taiwan study [54]. This likely reflects the 
increased behavioural and psychological symptoms of dementia as it progresses. The increased hospital 
visits we observed post Z-drug initiation could partly reflect the increased fracture and stroke rates in 
these patients. The Taiwan study also reported greater rates of fall-related injuries requiring 
hospitalization among Z-drug users [54].   
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Conclusions  
Higher doses of Z-drugs should be avoided in PlwD due to increased fracture and stroke risks. One in six 
PlwD in our study were commenced at 7.5mg zopiclone or equivalent daily. Prescribers should use the 
lowest effective dose in the elderly, use simple specific drug regimens, and this advice needs 
implementing in national guidelines [64,65]. Our findings suggest that the safety profile of Z-drugs should 
be considered similar to benzodiazepines in PlwD. Although the risks associated with low dose Z-drugs 
were small, as the effectiveness of Z-drugs is also unproven in dementia, we advise adhering to the Beers 
criteria guidelines of avoiding Z-drug use in PlwD, where possible [66]. Alternative strategies should be 
sought for sleep disturbance other than Z-drug or benzodiazepine dose escalation. Where 
pharmacological management of sleep disturbance is initiated, fracture risk management plans are 
implemented, and prescriptions regularly reviewed to mitigate potential adverse health outcomes. This 
gives a clear and important steer for the use of hypnotics in people with dementia in clinical practice. This 
evidence is currently particularly important as social isolation related to the COVID-19 pandemic may 
increase the frequency of neuropsychiatric symptoms in dementia [67], and limit resources to offer non-
pharmacological management approaches.  
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Table 1. Characteristics of patients with dementia prescribed Z-drugs and benzodiazepines and comparison 
cohorts  
 
Z-drug 
(n=3532) 
Sleep disturbance, 
no sedative-
hypnotic (n=1833) 
No Z-drug, proximal 
GP consultation 
(n=10214) 
Benzodiazepine 
(n=5172) 
No 
benzodiazepine, 
proximal GP 
consultation 
(n=15174) 
Characteristic  n % n % n % n % n % 
Women 2087 59% 1145 62% 6074 59% 3222 62% 9491 63% 
Age, yearsa 82.9 7.7 83.1 7.1 83.1 7.5 82.5 7.8 82.6 7.8 
White ethnicityb 3072 87% 1539 84% 8816 86% 4470 86% 13042 86% 
Care homeb 892 25% 434 24% 2108 21% 1509 29% 2979 20% 
Lives aloneb 760 22% 545 30% 2848 28% 993 19% 4785 32% 
GP practice area IMD quintilea 3.2 1.4 3.4 1.4 3.1 1.4 3.2 1.4 3.1 1.4 
Current smokerb 312 9% 142 8% 722 7% 355 7% 1124 7% 
Ex-smokerb 765 22% 428 23% 2226 22% 1163 22% 3322 22% 
Alcohol drinkerb 715 20% 489 27% 2142 21% 1127 22% 3297 22% 
Body mass indexab 24.9 4.9 24.5 4.6 24.9 4.8 24.5 4.8 24.8 4.9 
Systolic blood pressureab 133.5 19.0 133.9 18.8 134.3 19.1 133.6 18.9 134.5 18.8 
Dementia           
Months since dementia 
diagnosisc 
11.4 
3.6-
26.2 
11.0 3.8-24.1 13.5 5.2-27.4 15.6 5.1-32.4 10.3 3.7-22.0 
Dementia subtype           
Alzheimer's disease 1355 38% 746 41% 4224 41% 2140 41% 6612 44% 
Vascular dementia 940 27% 487 27% 2773 27% 1375 27% 4046 27% 
Other/mixed dementia 409 12% 192 10% 1013 10% 600 12% 1377 9% 
Unspecified dementia 828 23% 403 22% 2184 21% 1057 20% 3139 21% 
Agitation/psychosis history  619 18% 409 22% 1261 12% 1363 26% 1341 9% 
End of life care 197 6% 77 4% 564 6% 416 8% 726 5% 
Sleep disturbance           
Sleep disturbance pre dementia 825 23% 615 34% 1982 19% 1064 21% 2918 19% 
History of benzodiazepine use  869 25% 222 12% 1376 13% 982 19% 2009 13% 
History of Z-drug use  304 9% 113 6% 597 6% 481 9% 852 6% 
Medical history in past year           
Falls 1003 28% 542 30% 2165 21% 1241 24% 3359 22% 
Fractures 360 10% 131 7% 657 6% 409 8% 1071 7% 
Dizziness/unsteadiness 214 6% 127 7% 652 6% 294 6% 817 5% 
Faints/syncope 184 5% 120 7% 533 5% 357 7% 712 5% 
Urinary tract infection/acute LRTI 928 26% 423 23% 2054 20% 1242 24% 3114 21% 
Influenza vaccination 2480 70% 1340 73% 7747 76% 3739 72% 11350 75% 
Pneumonia vaccination  166 5% 103 6% 506 5% 234 5% 773 5% 
Physician consultationsa 12.5 10.3 11.2 9.4 14.9 12.7 12.9 10.7 13.7 12.0 
Hospital admissionsa 1.3 3.0 1.0 2.2 0.9 1.6 1.1 1.9 0.9 2.3 
Comorbidities   
  
  
    
Depression 894 25% 493 27% 2633 26% 1,512 29% 3,723 25% 
Depression symptoms 692 20% 368 20% 1898 19% 1,175 23% 2,804 18% 
Anxiety 576 16% 311 17% 1648 16% 1,204 23% 2,451 16% 
Anxiety symptoms 446 13% 261 14% 1181 12% 877 17% 1,751 12% 
Parkinson's disease 208 6% 109 6% 530 5% 290 6% 723 5% 
Urinary incontinence 520 15% 465 25% 1640 16% 841 16% 2,273 15% 
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Benign prostatic hyperplasia 361 10% 175 10% 1075 11% 487 9% 1,474 10% 
Asthma 366 10% 165 9% 1056 10% 517 10% 1,590 10% 
Cancer  743 21% 313 17% 2114 21% 1,002 19% 3,074 20% 
COPD 266 8% 147 8% 782 8% 369 7% 1,209 8% 
Osteoporosis 417 12% 215 12% 1224 12% 581 11% 1,885 12% 
Other muscleroskeletal 
conditions 
448 13% 248 14% 1395 14% 664 13% 2,036 13% 
Osteoarthritis/Rheumatoid 
Arthritis 
1426 40% 756 41% 3980 39% 2,063 40% 5,906 39% 
Other joint conditions 2901 82% 1,537 84% 8463 83% 4,293 83% 12,615 83% 
Headache/migraine 720 20% 363 20% 2020 20% 1,101 21% 2,955 19% 
Back/neck pain 1959 55% 1,009 55% 5640 55% 2,910 56% 8,380 55% 
Age-related macular 
degeneration 
189 5% 115 6% 648 6% 348 7% 923 6% 
Cataract 992 28% 547 30% 2940 29% 1,400 27% 4,284 28% 
Glaucoma 356 10% 186 10% 1011 10% 445 9% 1,459 10% 
Retinal disorder 295 8% 138 8% 944 9% 415 8% 1,390 9% 
Diabetes  531 15% 245 13% 1712 17% 718 14% 2,483 16% 
Hyperlipidaemia 470 13% 269 15% 1443 14% 754 15% 2,152 14% 
Hypertension 1822 52% 1,006 55% 5736 56% 2,762 53% 8,521 56% 
Stroke/transient ischemic attack 783 22% 397 22% 2177 21% 1,091 21% 3,022 20% 
Myocardial infarction 310 9% 172 9% 909 9% 433 8% 1,307 9% 
Heart failure 314 9% 182 10% 988 10% 444 9% 1,350 9% 
Atrial fibrillation 528 15% 260 14% 1666 16% 775 15% 2,365 16% 
Angina 532 15% 308 17% 1646 16% 811 16% 2,263 15% 
Venous thromboembolism 236 7% 123 7% 737 7% 341 7% 1,029 7% 
Prescriptions in last 90 days           
Anticholinesterase/memantine  850 24% 385 21% 2417 24% 1237 24% 3662 24% 
Antipsychotic  811 23% 371 20% 1586 16% 1125 22% 851 6% 
SSRI antidepressant 763 22% 352 19% 1855 18% 1174 23% 2616 17% 
Tricyclic antidepressant 363 10% 192 10% 835 8% 596 12%   
Other antidepressant 294 8% 153 8% 575 6% 483 9% 771 5% 
Antiepileptic 241 7% 110 6% 610 6% 424 8% 825 5% 
Analgesic 1730 49% 808 44% 4107 40% 2338 45% 5805 38% 
Inhaled corticosteroid 191 5% 96 5% 507 5% 196 4% 742 5% 
Lipid regulating medication 1217 34% 630 34% 3492 34% 1644 32% 5324 35% 
Diuretic 1188 34% 633 35% 3322 33% 1456 28% 4779 31% 
Beta blocker 645 18% 328 18% 1907 19% 850 16% 2771 18% 
ACE inhibitor 709 20% 379 21% 2222 22% 991 19% 3357 22% 
Angiotensin II receptor 
antagonist  
235 7% 124 7% 724 7% 330 6% 1123 7% 
Calcium channel blocker 643 18% 339 18% 1947 19% 849 16% 2980 20% 
Anticoagulant 204 6% 103 6% 739 7% 295 6% 1056 7% 
Antiplatelet 1603 45% 878 48% 4390 43% 2171 42% 6439 42% 
Cardiac glycoside 281 8% 155 8% 768 8% 345 7% 1032 7% 
NSAID 352 10% 156 9% 815 8% 468 9% 1206 8% 
Bisphosphonate 375 11% 194 11% 1074 11% 477 9% 1618 11% 
Calcium/Vitamin D 677 19% 377 21% 1854 18% 888 17% 2754 18% 
Antibiotic (in last 30 days) 1098 31% 567 31% 2590 25% 1370 26% 3640 24% 
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Abbreviations: ACE, Angiotensin-converting enzyme; COPD, Chronic Obstructive Pulmonary Disease; 
IMD, Index of Multiple Deprivation; GP, general practitioner; LRTI, Lower respiratory tract infection; 
NSAID, Nonsteroidal anti-inflammatory drug; SSRI, Selective serotonin reuptake inhibitor 
a mean (standard deviation) 
b Characteristic contains missing data as described in Additional file 5 table S2. 
c median (inter-quartile range)  
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Table 2. Adjusted hazard ratios for new Z-drug prescription and adverse events for people with dementia 
 
 
 Comparator 
Outcome 
Z-drug 
(n=3532) 
Sleep disturbance, no 
sedative-hypnotic 
(n=1833) 
No Z-drug, proximal 
GP consultation 
(n=10214)  
Benzodiazepine 
(n=5172) 
Fracture     
Incidence rate per 100PY (events) 11.4 (164) 7.6 (130) 8.4 (269) 12.5 (223) 
Age, sex adjusted HR (95% CI) NA 1.39 (1.08-1.78) 1.40 (1.14-1.70) 0.93 (0.76-1.14) 
Fully adjusted HR (95% CI)a NA 1.32 (0.99-1.75) 1.34 (1.08-1.67)b 0.99 (0.80-1.23) 
Hip fracture     
Incidence rate per 100PY (events) 5.7 (84) 3.4 (60) 3.5 (115) 5.1 (94) 
Age, sex adjusted HR (95% CI) NA 1.53 (1.07-2.18) 1.64 (1.23-2.19) 1.11 (0.82-1.49) 
Fully adjusted HR (95% CI)a NA 1.38 (0.92-2.06) 1.59 (1.15-2.19) b 1.10 (0.87-1.65) 
Forearm/wrist/hand fracture      
Incidence rate per 100PY (events) 2.0 (29) 1.1 (20) 1.5 (48) 2.5 (46) 
Age, sex adjusted HR (95% CI) NA 1.80 (0.95-3.41) 1.35 (0.85-2.14) 0.81 (0.51-1.28) 
Fully adjusted HR (95% CI)a NA 1.44 (0.60-3.47) 1.33 (0.77-2.31) 1.00 (0.59-1.70) 
Fall      
Incidence rate per 100PY (events) 37.1 (473) 27.3 (384) 25.8 (767) 35.8 (585) 
Age, sex adjusted HR (95% CI) NA 1.12 (0.97-1.29) 1.52 (1.36-1.71) 1.06 (0.94-1.20) 
Fully adjusted HR (95% CI)a NA 1.02 (0.87-1.21) 1.43 (1.26-1.62) b 1.08 (0.95-1.22) 
Mortality     
Incidence rate per 100PY (events) 28.4 (436) 16.7 (301) 24.1 (799) 39.0 (736) 
Age, sex adjusted HR (95% CI) NA 1.51 (1.29-1.77) 1.20 (1.06-1.34) 0.72 (0.64-0.81) 
Fully adjusted HR (95% CI)a NA 1.38 (1.14-1.66) b 1.08 (0.94-1.23) 0.73 (0.64-0.83) b 
Acute bacterial infection      
Incidence rate per 100PY (events) 47.8 (416) 43.6 (220) 40.6 (1325) 57.8 (371) 
Age, sex adjusted HR (95% CI) NA 1.13 (0.94-1.37) 1.24 (1.09-1.42) 1.01 (0.86-1.18) 
Fully adjusted HR (95% CI)a NA 1.02 (0.82-1.27) 1.13 (0.98-1.31) 0.92 (0.78-1.10) 
Ischemic stroke/ transient ischemic attack   
Incidence rate per 100PY (events) 6.2 (93) 4.4 (77) 5.5 (178) 6.0 (110) 
Age, sex adjusted HR (95% CI) NA 1.32 (0.95-1.83) 1.20 (0.94-1.54) 1.03 (0.78-1.36) 
Fully adjusted HR (95% CI)a NA 1.35 (0.90-2.04) 1.14 (0.86-1.50) 1.05 (0.78-1.43) 
Venous thromboembolism      
Incidence rate per 100PY (events) 1.5 (22) 1.3 (21) 1.4 (43) 2.5 (47) 
Age, sex adjusted HR (95% CI) NA 1.64 (0.97-2.79) 1.14 (0.74-1.76) 0.79 (0.50-1.25) 
Fully adjusted HR (95% CI)a NA 1.65 (0.74-3.69)c 1.12 (0.67-1.85) 0.82 (0.50-1.34) 
Abbreviations: HR, hazard ratio; CI, confidence interval; GP, general practitioner; PY, person-years. 
a Adjusted for all covariates listed in Table 1. 
b Fully-adjusted HR remaining statistically significant after controlling the false discovery rate to <5% 
(based on 13 outcomes) 
c not adjusted for antiepileptics, antiplatelet drugs, pneumonia vaccine and anxiety symptoms due to model 
instability 
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Table 3. Adjusted hazard ratios for Z-drug prescription and adverse events for people with dementia 
according to prescribed Daily Defined Dose of Z-drugs 
 
  
No. 
events Sleep disturbance and no sedative-
hypnotic (n=1833) 
No Z-drug, proximal GP consultation 
(n=10214) 
Outcome and 
 in Z-
drug 
Daily Defined 
Dose prescribeda  
cohort 
Age, sex 
adjusted   
Fully adjustedb  Age, sex adjusted   Fully adjustedb 
Fracture       
≤0.5 117 1.30 (0.99-1.70) 1.22 (0.90-1.66) 1.33 (1.07-1.65) 1.28 (1.01-1.63) 
0.6-0.9 5 1.28 (0.51-3.20) 1.06 (0.39-2.89) 1.24 (0.50-3.05) 1.08 (0.42-2.76) 
≥1 42 1.70 (1.19-2.42) 1.67 (1.13-2.46)c 1.66 (1.18-2.34) 1.58 (1.09-2.28) c 
Hip fracture   
    
≤0.5 55 1.30 (0.88-1.93) 1.21 (0.78-1.90) 1.42 (1.03-1.97) 1.43 (1.00-2.06) 
0.6-0.9 <5 1.10 (0.26-4.67) 0.79 (0.15-4.11) 1.27 (0.31-5.22) 1.05 (0.24-4.64) 
≥1 27 2.30 (1.45-3.65) 1.96 (1.16-3.31) c 2.50 (1.61-3.89) 2.36 (1.44-3.87) c 
Forearm fracture     
≤0.5 20 1.66 (0.81-3.40) 1.22 (0.48-3.12) 1.28 (0.77-2.15) 1.29 (0.73-2.27) 
≥0.6 9 2.18 (0.98-4.85) 1.91 (0.67-5.47) 1.53 (0.72-3.24) 1.42 (0.59-3.38) 
Fall  
    
≤0.5 335 1.05 (0.90-1.22) 0.95 (0.80-1.13) 1.43 (1.26-1.63) 1.35 (1.17-1.56) c 
0.6-0.9 14 0.84 (0.49-1.44) 0.73 (0.41-1.29) 1.19 (0.70-2.02) 1.07 (0.61-1.87) 
≥1 124 1.42 (1.15-1.74) 1.33 (1.06-1.66) c 1.92 (1.58-2.35) 1.81 (1.46-2.34) c 
Mortality  
    
≤0.5 321 1.49 (1.26-1.77) 1.38 (1.14-1.68) c 1.18 (1.03-1.34) 1.07 (0.93-1.24) 
0.6-0.9 16 1.56 (0.95-2.56) 1.60 (0.96-2.70) 1.25 (0.77-2.02) 1.22 (0.75-1.99) 
≥1 99 1.56 (1.24-1.96) 1.33 (1.03-1.71) 1.26 (1.02-1.55) 1.06 (0.85-1.33) 
Acute bacterial infection     
≤0.5 297 1.15 (0.98-1.36) 1.00 (0.83-1.20) 1.37 (1.20-1.57) 1.23 (1.06-1.43) c 
0.6-0.9 13 0.98 (0.56-1.72) 0.86 (0.47-1.57) 1.20 (0.69-2.08) 1.12 (0.63-1.99) 
≥1 106 1.40 (1.12-1.76) 1.25 (0.98-1.60) 1.64 (1.32-2.04) 1.52 (1.21-1.91) c 
Ischemic stroke/transient ischemic attack   
≤0.5 55 1.04 (0.72-1.51) 1.12 (0.71-1.75) 0.96 (0.71-1.30) 0.95 (0.68-1.31) 
0.6-0.9 5 1.97 (0.78-4.96) 1.98 (0.74-5.28) 1.74 (0.72-4.19) 1.71 (0.74-3.98) 
≥1 33 2.07 (1.36-3.15) 1.88 (1.14-3.10) c 1.90 (1.30-2.79) 1.61 (1.08-2.42) 
Venous thromboembolism     
≤0.5 26 2.01 (1.16-3.49) 2.00 (0.90-4.47) 1.35 (0.85-2.13) 1.26 (0.74-2.12) 
≥0.6 <5 0.78 (0.27-2.25) 0.85 (0.21-3.39) 0.56 (0.21-1.54) 0.66 (0.22-1.95) 
 
Abbreviations: HR, hazard ratio; CI, confidence interval; GP, general practitioner 
a The reference group for all comparisons is no Z-drug prescription. Most patients assigned to the ‘0.6-0.9 
DDD’ Z-drug group were prescribed 3.75mg zopiclone with instructions similar to “TAKE ONE OR TWO 
AT NIGHT”. 
b Adjusted for all covariates listed in table 1. 
c Fully-adjusted HR remaining statistically significant after controlling the false discovery rate to <5% 
(based on 37 tests; 11 outcomes with three dose categories and two outcomes with two dose categories) 
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Table 4. Adjusted hazard and rate ratios for new Z-drug prescription and new prescriptions, GP 
consultations and hospital admissions for people with dementia 
 
 
 Comparator 
Outcome 
Z-drug 
(n=3,532) 
Sleep 
disturbance, no 
sedative-hypnotic 
(n=1833) 
No Z-drug, proximal 
GP consultation 
(n=10214) 
Benzodiazepine 
(n=5172) 
Number of hospital admissions      
Rate per 100PY (events) 126.7 (1944) 93.0 (1671) 107.7 (3563) 129.4 (2441) 
Age, sex adjusted RR (95% CI) NA 1.34 (1.20-1.49) 1.26 (1.15-1.39) 0.98 (0.89-1.09) 
Fully adjusted RR (95% CI)a NA 1.26 (1.13-1.40)b 1.17 (1.07-1.27) b 0.92 (0.84-1.01) 
Number of GP consultations      
Rate per 100PY (events) 1387.8 (21292) 1124.6 (20209) 1511.7 (50021) 1502.6 (28335) 
Age, sex adjusted RR (95% CI) NA 1.29 (1.22-1.37) 0.97 (0.93-1.01) 0.94 (0.90-0.98) 
Fully adjusted RR (95% CI)a  NA 1.17 (1.12-1.23) b 1.07 (1.04-1.11) b 0.96 (0.93-1.00) 
New antipsychotic prescription      
Incidence rate per 100PY (events) 38.7 (331) 10.3 (130) 15.2 (227) 75.4 (532) 
Age, sex adjusted HR (95% CI) NA 2.53 (2.03-3.14) 3.68 (3.10-4.37) 0.79 (0.68-0.90) 
Fully adjusted HR (95% CI)a NA 2.37 (1.84-3.04) b 3.85 (3.18-4.65) b 0.86 (0.74-0.99) 
New antidepressant prescription      
Incidence rate per 100PY (events) 23.8 (172) 8.2 (82) 10.3 (199) 30.3 (242) 
Age, sex adjusted HR (95% CI) NA 2.24 (1.70-2.94) 2.52 (2.05-3.10) 0.86 (0.71-1.05) 
Fully adjusted HR (95% CI)a NA 2.32 (1.65-3.25) b 2.65 (2.09-3.37) b 0.88 (0.71-1.10) 
New antibiotic prescription      
Incidence rate per 100PY (events) 109.1 (791) 61.2 (517) 89.5 (1738) 111.0 (1096) 
Age, sex adjusted HR (95% CI) NA 1.46 (1.30-1.65) 1.27 (1.17-1.38) 1.01 (0.92-1.10) 
Fully adjusted HR (95% CI)a NA 1.34 (1.17-1.52) b 1.19 (1.08-1.30) b 1.05 (0.95-1.15) 
 
Abbreviations: HR, hazard ratio; CI, confidence interval; PY, person-years; RR, rate ratio. 
a Adjusted for all covariates listed in table 1. 
b Fully-adjusted HR remaining statistically significant after controlling the false discovery rate to <5% 
(based on 13 outcomes) 
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Table 5. Adjusted hazard ratios for Z-drug prescription and new prescriptions, GP consultations and hospital admissions for people with 
dementia according to prescribed Daily Defined Doses (DDDs) of Z-drugs  
 
 No. events No sedative-hypnotic, sleep disturbance 
(n=1833) 
No Z-drug, proximal GP consultation 
(n=10214) Outcome and  in Z-drug 
daily defined dose 
prescribeda  
cohort Age, sex adjusted Fully adjustedb Age, sex adjusted Fully adjustedb 
Number of hospital admissionsc    
≤0.5 1403 1.24 (1.10-1.39) 1.18 (1.05-1.32) 1.19 (1.07-1.31) 1.10 (1.00-1.20) 
0.6-0.9 63 1.06 (0.76-1.49) 1.22 (0.88-1.69) 1.03 (0.74-1.43) 1.10 (0.80-1.51) 
≥1 472 1.35 (1.15-1.58) 1.29 (1.10-1.50)d 1.32 (1.15-1.52) 1.22 (1.06-1.39) d 
Number of GP consultationsc     
≤0.5 9230 1.21 (1.14-1.29) 1.10 (1.05-1.16) d 0.89 (0.85-0.94) 1.00 (0.96-1.04) 
0.6-0.9 690 1.12 (0.96-1.32) 1.10 (0.95-1.26) 0.83 (0.71-0.97) 1.02 (0.88-1.17) 
≥1 4823 1.23 (1.12-1.34) 1.16 (1.08-1.25) d 0.91 (0.84-0.98) 1.06 (0.99-1.13) 
Incident antipsychotic prescription    
≤0.5 214 2.08 (1.64-2.62) 2.00 (1.54-2.61) d 3.09 (2.56-3.74) 3.31 (2.69-4.07) d 
0.6-0.9 18 3.35 (2.04-5.50) 2.75 (1.57-4.81) d 5.15 (3.19-8.32) 4.82 (2.81-8.25) d 
≥1 99 4.05 (3.10-5.31) 3.56 (2.61-4.85) d 5.81 (4.55-7.42) 5.82 (4.44-7.63) d 
Incident antidepressant prescription    
≤0.5 124 1.25 (1.14-1.37) 1.16 (1.05-1.28) d 2.47 (1.91-3.19) 2.39 (1.90-2.99) d 
0.6-0.9 8 1.20 (0.83-1.73) 1.13 (0.76-1.68) 2.67 (1.19-5.99) 3.00 (1.49-6.01) 
≥1 40 1.37 (1.17-1.61) 1.31 (1.11-1.54) d 3.47 (2.32-5.18) 2.93 (2.04-4.19) d 
Incident antibiotic prescription    
≤0.5 583 1.43 (1.27-1.63) 1.30 (1.13-1.49) d 1.25 (1.14-1.37) 1.16 (1.05-1.28) d 
0.6-0.9 27 1.36 (0.93-2.00) 1.20 (0.79-1.81) 1.20 (0.83-1.73) 1.13 (0.76-1.68) 
≥1 181 1.57 (1.32-1.88) 1.46 (1.21-1.76) d 1.37 (1.17-1.61) 1.31 (1.11-1.54) d 
 
Abbreviations: HR, hazard ratio; CI, confidence interval; GP, general practitioner. 
a The reference group for all comparisons is no Z-drug prescription. Most patients assigned to the ‘0.6-0.9 DDD’ Z-drug group were prescribed 
3.75mg zopiclone with instructions similar to “TAKE ONE OR TWO AT NIGHT”. 
b Adjusted for all covariates listed in table 1. 
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c Estimates provided are Rate Ratios (95% confidence intervals) 
d Fully-adjusted HR remaining statistically significant after controlling the false discovery rate to <5% (based on 37 tests; 11 outcomes with 
three dose categories and two outcomes with two dose categories) 
 
